Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
188
Views
0
CrossRef citations to date
0
Altmetric
REVIEW

Recalcitrant Pyoderma Gangrenosum: Clinical Burden and Unmet Needs

Sarah L Becker1 Department of Dermatology, Oregon Health & Science University, Portland, OR, USA
,
Rose Velasco2 University of Illinois College of Medicine, Chicago, IL, USA
&
Alex G Ortega-Loayza1 Department of Dermatology, Oregon Health & Science University, Portland, OR, USACorrespondence[email protected]
Pages 2143-2152 | Received 29 May 2023, Accepted 29 Jul 2023, Published online: 09 Aug 2023

References

  • Langan SM, Groves RW, Card TR, et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Investig Dermatol. 2012;132(9):2166–2170. doi:10.1038/jid.2012.130
  • Alavi A, French LE, Davis MD, et al. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2017;18(3):355–372. doi:10.1007/s40257-017-0251-7
  • Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23(9):1008–1017. doi:10.1111/j.1468-3083.2009.03199.x
  • Wollina U. Pyoderma gangrenosum--a review. Orphanet J Rare Dis. 2007;2:19. doi:10.1186/1750-1172-2-19
  • Ashchyan HJ, Butler DC, Nelson CA, et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol. 2018;154(4):409–413. doi:10.1001/jamadermatol.2017.5978
  • Orfaly VE, Reese AM, Friedman M, et al. Pyoderma gangrenosum study pilot registry: the first step to a better understanding. Wound Repair Regen. 2022;30(3):334–337. doi:10.1111/wrr.13005
  • Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73(4):691–698. doi:10.1016/j.jaad.2015.06.021
  • Haag C, Hansen T, Hajar T, et al. Comparison of three diagnostic frameworks for pyoderma gangrenosum. J Invest Dermatol. 2021;141(1):59–63. doi:10.1016/j.jid.2020.04.019
  • Almeida IR, Coltro PS, Gonçalves HOC, et al. The role of negative pressure wound therapy (NPWT) on the treatment of pyoderma gangrenosum: a systematic review and personal experience. Wound Repair Regen. 2021;29(3):486–494. doi:10.1111/wrr.12910
  • Xu A, Balgobind A, Strunk A, et al. Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis. J Am Acad Dermatol. 2020;83(2):425–429. doi:10.1016/j.jaad.2019.08.001
  • Machan A, Azendour H, Frikh R, et al. The dilemma of treating pyoderma gangrenosum associated with monoclonal gammopathy of undetermined significance. Dermatol Online J. 2020;26(5). doi:10.5070/D3265048791
  • Reese AM, Gupta AS, Latour E, et al. Clinical characteristics and misdiagnosis of pyoderma gangrenosum of the head and neck: a retrospective study. J Am Acad Dermatol. 2022;87(5):1130–1133.
  • Chow RK, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol. 1996;34(6):1047–1060. doi:10.1016/S0190-9622(96)90285-6
  • Quist SR, Kraas L. Treatment options for pyoderma gangrenosum. J Dtsch Dermatol Ges. 2017;15(1):34–40.
  • Ormerod AD, Thomas KS, Craig FE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:h2958. doi:10.1136/bmj.h2958
  • Yamasaki K, Yamanaka K, Zhao Y, et al. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: twenty-six-week Phase 3 open-label study. J Dermatol. 2020;47(12):1383–1390. doi:10.1111/1346-8138.15533
  • Herberger K, Dissemond J, Brüggestrat S, Sorbe C, Augustin M. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients. J Dtsch Dermatol Ges. 2019;17(1):32–41.
  • Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther. 2013;38(6):563–572. doi:10.1111/apt.12431
  • Mital R, Gray A, Minta A, et al. Novel and off-label biologic use in the management of hidradenitis suppurativa, pyoderma gangrenosum, lichen planus, and seborrheic dermatitis: a narrative review. Dermatol Ther. 2023;13(1):77–94. doi:10.1007/s13555-022-00860-5
  • Maronese CA, Pimentel MA, Li MM, et al. Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol. 2022;23(5):615–634. doi:10.1007/s40257-022-00699-8
  • Weenig RH, Davis MDP, Dahl PR, et al. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med. 2002;347(18):1412–1418. doi:10.1056/NEJMoa013383
  • Orfaly VE, Kovalenko I, Tolkachjov SN, et al. Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol. 2021;46(6):1082–1085. doi:10.1111/ced.14683
  • Malachowski SJ, Latour E, Ortega-Loayza AG. Clinical and laboratory factors associated with wound healing in patients with pyoderma gangrenosum: a retrospective study. Wounds. 2022;34(6):178–184. doi:10.25270/wnds/2022.0408

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.